Research Paper Volume 12, Issue 6 pp 5183—5194

LncRNA AGAP2-AS1 augments cell viability and mobility, and confers gemcitabine resistance by inhibiting miR-497 in colorectal cancer

Figure 5. AGAP2-AS1 sponged miR-497 and modulated FGFR1 expression. (A) Subcellular localization of AGAP2-AS1 was detected in RKO cell line. (B) miR-497-binding sequence in AGAP2-AS1 and FGFR1 3'UTR. (C) Luciferase activity of pLuc-AGAP2-AS1 WT or Mut co-transfected with miR-497. (D) Cellular lysates from RKO cells were used for RIP with an anti-Ago2 antibody or IgG antibody. (E) miR-497 and pLuc-FGFR1 3'UTR were co-transfected with pWPXL-AGAP2-AS1 into 293T cells. (F) The expression level of FGFR1 in RKO cells transfected with pWPXL-AGAP2-AS1 and in DLD-1 cells transfected with si-AGAP2-AS1. (G) Correlation between FGFR1 and AGAP2-AS1 expression. *P < 0.05; **P < 0.01.